Skip to main content

Table 1 Characteristics of individuals living with HIV at diagnosis and follow up (total N = 1160)

From: Determinants of AIDS and non-AIDS related mortality among people living with HIV in Shiraz, southern Iran: a 20-year retrospective follow-up study

Baseline CharacteristicsEntire cohortAIDS-related mortalityNon-AIDS-related mortalityAll-cause mortality
Overall1160 (100)*251 (21.6)140 (12.1)391 (33.7)
Gender
 Men857 (73.9)215 (25.1)136 (15.9)351 (41.0)
 Women303 (26.1)36 (11.9)4 (1.3)40 (13.2)
Age
 Median (Q1, Q3)34 (29–40)36 (30–43)35 (30–41)35 (30–42)
 < 30309 (26.6)55 (17.8)34 (11.0)89 (28.8)
 30–39545 (47.0)108 (19.8)61 (11.2)169 (31.0)
 > =40306 (26.4)88 (28.8)45 (14.7)133 (43.5)
Marital status
 Married526 (45.3)101 (19.2)48 (9.1)149 (28.3)
 Single303 (26.2)81(26.7)50 (16.5)131 (43.2)
 Widowed/divorced331 (28.5)69 (20.8)42 (12.7)111 (3.4)
Education
 Less than secondary403 (34.7)93 (23.0)50 (12.4)143 (35.5)
 Secondary or more757 (65.3)158 (20.8)90 (11.8)237 (31.3)
Employment
 Employed549 (47.3)112 (20.4)77 (14.0)189 (34.4)
 Unemployed611 (52.7)139 (22.7)63 (10.3)202 (33.1)
Incarceration history
 No392 (33.8)48 (12.2)10 (2.6)58 (14.8)
 Yes768 (66.2)203 (26.4)130 (16.9)333 (43.4)
Mode of HIV transmission
 Sexual344 (29.7)46 (13.4)9 (2.6)55 (16.0)
 Injection drug use733 (63.2)185(25.2)123 (16.8)308 (42.0)
 Othersa83 (7.1)20 (24.1)8 (9.6)28(33.7)
 CD4 count
Median (Q1, Q3)
215 (102,352)238 (127,254)133 (63,260)163 (78,300)
Year HIV was diagnosed
 Before 2011712 (61.4)46 (6.4)35 (4.9)81 (11.3)
 2011–2014306 (26.4)145 (47.3)69 (22.5)214 (69.8)
 2015–2017142 (12.2)60 (42.2)36 (25.3)96(67.5)
Covariates measured at follow-up
 Drug use status
  No drug use307 (26.5)36 (11.7)5 (1.6)41 (16.0)
  On methadone therapy568 (49.0)101 (17.8)65 (11.4)166 (42.0)
  Drug users258 (24.5)114 (44.2)70 (27.1)184 (33.7)
Linkage to HIV care
 No219 (18.9)124 (56.6)72 (32.9)196 (89.5)
 Yes941(81.1)127 (13.5)68 (7.2)195 (20.7)
Responded HAART 6 month after initiationb
 No392 (33.8)239 (61)97 (24.7)232 (59.2)
 Yes768 (66.2)12 (1.6)43 (5.6)159 (20.7)
Late HIV diagnosis
 No629 (54.2)136 (21.6)96 (15.3)232 (36.9)
 Yes531 (45.8)115 (21.7)44 (8.3)159 (29.9)
TB status
 Negative1048 (90.3)205 (19.6)123 (11.7)328 (31.3)
 Positive112 (9.7)46 (41.0)17 (15.2)63 (56.3)
PCP prophylaxis
 No480 (41.4)108 (22.5)77 (16.0)185 (38.5)
 Yes680 (58.6)143 (21)63 (9.3)206 (30.3)
HCV positive co-infection
 Negative500 (43.1)116 (23.2)33 (6.6)149 (29.8)
 Positive660 (56.9)135 (20.5)107 (16.2)242 (36.7)
HBV positive co-infection
 Negative1078 (92.9)231 (21.4)127 (11.8)358 (33.2)
 Positive82 (7.1)20 (24.4)13 (15.9)33 (40.2)
Last clinical stage
 1,2832 (71.7)24 (2.9)91 (10.9)115 (13.8)
 3,4328 (28.3)227 (69.2)49 (14.9)276 (84.1)
  1. * Data are presented as N (%)
  2. aOther modes of transmission included: who infected HIV with unknown cause, blood transition or through dentistry
  3. binclude those showing an improvement in clinical factors or increased CD4 counts 6 months after HAART treatment based on medical records and physicians’ comments